SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has been featured in a BioMedWire editorial examining the rapid expansion of the GLP-1 market, with the company’s subsidiary GlucaPharm Inc. and its development of GEP-44 positioned as a next-generation candidate to address limitations of current therapies. The editorial notes that GEP-44, a patented triple agonist peptide licensed from Syracuse University, targets GLP-1 and peptide YY receptors Y1 and Y2, aiming to improve efficacy, tolerability and delivery flexibility.
The coverage places SureNano alongside established and emerging metabolic disease companies including Merck & Co. (NYSE: MRK), AbbVie (NYSE: ABBV), Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT), underscoring accelerating momentum across the obesity, diabetes and cardiometabolic treatment landscape. The editorial highlights SureNano’s broader platform strategy, which includes evaluating oral, sublingual and intranasal delivery approaches, as well as early-stage opportunities involving formulation and delivery technologies that could expand the company’s long-term therapeutic scope.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. Through its acquisition of GlucaPharm Inc., the company is developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery, as referenced in a press release dated February 23, 2026. The initial business of SureNano Science Ltd. involves the sale and distribution of the SureNano™ surfactant, a ready-to-mix food grade compound for nanoemulsions, with exclusive distribution licenses in Canada, Oklahoma, and Colorado. The company is now transitioning into a pharmaceutical-focused entity through the advancement of this therapeutic candidate.
The editorial from BioMedWire, a brand within the Dynamic Brand Portfolio @IBN, provides analysis of the growing GLP-1 market and SureNano’s potential role. The full press release is available at https://ibn.fm/2NGrw. For more information on SureNano, including latest news and updates, visit the company’s newsroom at https://ibn.fm/SURNF.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SureNano Science’s GLP-1 Triple Agonist GEP-44 Targets Next-Generation Obesity Treatment.